# Mangoceuticals, Inc.: filings

MGRX · Nasdaq · CIK 1938046 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mgrx.md) · [Financials](/companies/mgrx/financials.md) · [Filings](/companies/mgrx/filings.md) · [Insiders](/companies/mgrx/insiders.md)

## Reports and events: 116 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (8-K 78, 4 31, CORRESP 21, 10-Q 11, UPLOAD 10, 3 8, EFFECT 8, S-1/A 7, S-1 6, 425 5, 144 4, S-8 4, 10-K 3, DEF 14A 3, DRSLTR 3, POS AM 3, PRE 14A 3, SC 13D/A 3, SCHEDULE 13D/A 3, 144/A 2, 424B3 2, 424B4 2, 424B5 2, DRS 2, DRS/A 2, SEC STAFF LETTER 2, 10-Q/A 1, 8-A12B 1, ARS 1, AW 1, CERT 1, D 1, D/A 1, NT 10-K 1, NT 10-Q 1, S-3 1, SC 13D 1, SCHEDULE 13G 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-09 | 20:01 ET | [8-K](/filings/0001493152-26-046510.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-046510 |
| 2026-10-06 | 12:00 ET | [SCHEDULE 13D/A](/filings/0001493152-26-045857.md) | Ownership report, active investor, amended | 0001493152-26-045857 |
| 2026-10-01 | 19:50 ET | [8-K](/filings/0001493152-26-045341.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-045341 |
| 2026-08-21 | 21:15 ET | [8-K](/filings/0001493152-26-039724.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-039724 |
| 2026-08-13 | 21:27 ET | [10-Q](/filings/0001493152-26-037873.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037873 |
| 2026-08-04 | 20:05 ET | [8-K](/filings/0001493152-26-035993.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-035993 |
| 2026-07-30 | 11:00 ET | [8-K](/filings/0001493152-26-035323.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035323 |
| 2026-07-02 | 20:30 ET | [8-K](/filings/0001493152-26-031917.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-031917 |
| 2026-05-19 | 20:30 ET | [10-Q](/filings/0001493152-26-024426.md) | Quarterly report, period 2026-03-31 | 0001493152-26-024426 |
| 2026-04-01 | 10:31 ET | [10-K](/filings/0001493152-26-014478.md) | Annual report, period 2025-12-31 | 0001493152-26-014478 |
| 2026-03-17 | 20:00 ET | [8-K](/filings/0001493152-26-010526.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-010526 |
| 2026-02-23 | 21:05 ET | [8-K](/filings/0001493152-26-007750.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-007750 |
| 2026-02-19 | 21:05 ET | [8-K](/filings/0001493152-26-007468.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-007468 |
| 2026-02-06 | 21:30 ET | [8-K](/filings/0001493152-26-005587.md) | 3.01 Delisting notice | 0001493152-26-005587 |
| 2026-01-23 | 22:07 ET | [S-1/A](/filings/0001493152-26-003446.md) | Registration statement, amended | 0001493152-26-003446 |
| 2026-01-13 | 22:30 ET | [S-1](/filings/0001493152-26-002093.md) | Registration statement | 0001493152-26-002093 |
| 2025-12-19 | 14:28 ET | [8-K](/filings/0001493152-25-028463.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-028463 |
| 2025-12-19 | 12:30 ET | [8-K](/filings/0001493152-25-028444.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-028444 |
| 2025-12-10 | 11:40 ET | [8-K](/filings/0001493152-25-027009.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001493152-25-027009 |
| 2025-11-14 | 22:17 ET | [10-Q](/filings/0001493152-25-023640.md) | Quarterly report, period 2025-09-30 | 0001493152-25-023640 |
| 2025-11-14 | 21:37 ET | [10-Q/A](/filings/0001493152-25-023566.md) | Quarterly report, amended, period 2025-06-30 | 0001493152-25-023566 |
| 2025-11-14 | 12:00 ET | [8-K](/filings/0001493152-25-022505.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-022505 |
| 2025-11-13 | 12:00 ET | [8-K](/filings/0001493152-25-022103.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-022103 |
| 2025-10-29 | 23:28 ET | [8-K](/filings/0001493152-25-019941.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-25-019941 |
| 2025-09-30 | 20:59 ET | [SCHEDULE 13D/A](/filings/0001493152-25-016353.md) | Ownership report, active investor, amended | 0001493152-25-016353 |
| 2025-09-12 | 20:33 ET | [8-K](/filings/0001493152-25-013213.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-25-013213 |
| 2025-09-02 | 20:30 ET | [8-K](/filings/0001493152-25-012557.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-012557 |
| 2025-08-14 | 20:31 ET | [10-Q](/filings/0001493152-25-011994.md) | Quarterly report, period 2025-06-30 | 0001493152-25-011994 |
| 2025-08-04 | 13:00 ET | [8-K](/filings/0001493152-25-011557.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-011557 |
| 2025-07-23 | 23:24 ET | [8-K](/filings/0001493152-25-011336.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-011336 |
| 2025-07-10 | 21:32 ET | [8-K](/filings/0001641172-25-018467.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001641172-25-018467 |
| 2025-07-03 | 21:27 ET | [8-K](/filings/0001641172-25-017879.md) | 5.02 Departure or appointment of officers or directors | 0001641172-25-017879 |
| 2025-06-10 | 21:00 ET | [8-K](/filings/0001641172-25-014545.md) | 3.02 Unregistered sale of equity | 0001641172-25-014545 |
| 2025-05-30 | 20:31 ET | [S-1](/filings/0001641172-25-013052.md) | Registration statement | 0001641172-25-013052 |
| 2025-05-30 | 23:46 ET | [8-K](/filings/0001641172-25-012917.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001641172-25-012917 |
| 2025-05-23 | 21:27 ET | [8-K](/filings/0001641172-25-012336.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001641172-25-012336 |
| 2025-05-15 | 20:58 ET | [10-Q](/filings/0001641172-25-011047.md) | Quarterly report, period 2025-03-31 | 0001641172-25-011047 |
| 2025-05-06 | 21:01 ET | [8-K](/filings/0001641172-25-008878.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001641172-25-008878 |
| 2025-04-25 | 13:00 ET | [8-K](/filings/0001641172-25-006122.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001641172-25-006122 |
| 2025-04-17 | 21:00 ET | [8-K](/filings/0001641172-25-005263.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001641172-25-005263 |
| 2025-04-11 | 21:00 ET | [8-K](/filings/0001641172-25-003881.md) | 5.02 Departure or appointment of officers or directors | 0001641172-25-003881 |
| 2025-04-11 | 21:00 ET | [SCHEDULE 13D/A](/filings/0001641172-25-003879.md) | Ownership report, active investor, amended | 0001641172-25-003879 |
| 2025-04-08 | 21:00 ET | [8-K](/filings/0001641172-25-003245.md) | 3.02 Unregistered sale of equity | 0001641172-25-003245 |
| 2025-04-02 | 20:59 ET | [8-K](/filings/0001493152-25-011197.md) | 3.02 Unregistered sale of equity | 0001493152-25-011197 |
| 2025-03-28 | 21:00 ET | [8-K](/filings/0001493152-25-011191.md) | 3.02 Unregistered sale of equity | 0001493152-25-011191 |
| 2025-03-25 | 13:00 ET | [8-K](/filings/0001641172-25-000525.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001641172-25-000525 |
| 2025-03-20 | 21:29 ET | [10-K](/filings/0001641172-25-000085.md) | Annual report, period 2024-12-31 | 0001641172-25-000085 |
| 2025-03-19 | 13:00 ET | [8-K](/filings/0001493152-25-010875.md) | 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-25-010875 |
| 2025-02-19 | 22:00 ET | [8-K](/filings/0001493152-25-007597.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-007597 |
| 2025-02-18 | 14:00 ET | [DEF 14A](/filings/0001493152-25-007103.md) | Proxy statement, period 2025-02-18 | 0001493152-25-007103 |

Page 1 of 3. [Older](/companies/mgrx/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. No prices; not investment advice.